Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Brigham and Women's Hospital
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04899908CT.gov Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aguix (this asset) | Brigham and Women's Hospital | P2 | CCC · 53 |
| Irinotecan | University of California, Davis | P2 | BBB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Cyclophosphamide | Essen Biotech | P2 | BB |
| Sorafenib | Virginia Commonwealth University | P2 | BB |
| Dianhydrogalactitol | Kintara Therapeutics, Inc. | P2 | BB |
| Capecitabine | Northwell Health | P2 | B |
| Carboplatin | John L. Villano, MD, PhD | P3 | B |
| Vorinostat | Duke University | P2 | B |
+42 more in the Brain Cancer cohort
Other indications for Aguix
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Digestive System Cancer | — | P2 | CCC · 53 |
| Central Nervous System Cyst | — | P2 | CCC · 53 |
| Brain Neoplasm | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aguix in Brain Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/aguix-brain-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →